Christen Douglas Forbes from 105 Village St, North Haven, CT 06473, age 53, Phone: (203)2347404

Methods For Screening And Identifying Compounds
view source
US Patent:

20120135417, May 31, 2012
Filed:

Jun 2, 2010
Appl. No.:

13/375865
Inventors:

Kenneth F. Blount - Guilford CT, US
Christen Douglas Forbes - North Haven CT, US
David Osterman - Glastonbury CT, US
International Classification:

C12Q 1/68
US Classification:

435 612, 435 613
Abstract:

Methods, compositions and assays that measure the effect of a test compound on induction of ligand-induced ribowitch-mediated transcription termination are disclosed. The methods and the assays are useful in identifying drug candidates that modulate transcription by binding to a riboswitch, for example.

High Throughput Method For Measuring The Protease Activity Of Complement C3 Convertase
view source
US Patent:

20210025886, Jan 28, 2021
Filed:

Mar 21, 2019
Appl. No.:

16/981008
Inventors:

- Boston MA, US
Christen D. FORBES - North Haven CT, US
Assignee:

Alexion Pharmaceuticals, Inc. - Boston MA
International Classification:

G01N 33/564
G01N 33/542
Abstract:

Provided herein are high throughput methods for measuring the protease activity of the complement C3 convertase by detecting the consumption of C3 or the production of C3a in vivo and in vitro.

Lysosomal Acid Lipase Deficiency Compositions And Methods
view source
US Patent:

20190151420, May 23, 2019
Filed:

Jun 16, 2017
Appl. No.:

16/308558
Inventors:

- Boston MA, US
John V.W. Reynders - Newton MA, US
Guillermo del Angel - Lexington MA, US
Nina Jain - North Andover MA, US
Christen D. Forbes - North Haven CT, US
Barbara Burton - Chicago IL, US
Assignee:

ALEXION PHARMACEUTICALS, INC. - Boston MA
International Classification:

A61K 38/46
C12Q 1/6883
C12Q 1/6853
C12Q 1/6858
A61P 1/16
A61P 1/02
Abstract:

Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human LIPA gene. Some LIPA gene products have been discovered to be associated with reduced lysosomal acid lipase (LAL) activity.

N-Acetyl-Alpha-D-Glucosaminidase Deficiency Compositions And Methods
view source
US Patent:

20180105879, Apr 19, 2018
Filed:

Oct 11, 2017
Appl. No.:

15/730382
Inventors:

- New Haven CT, US
Andrew Hutchinson - Stamford CT, US
Nina Jain - North Andover MA, US
Christen D. Forbes - North Haven CT, US
International Classification:

C12Q 1/68
A61K 38/47
Abstract:

Compositions and methods relating to potentially pathogenic mutations in the nucleotide sequence of a human NAGLU gene. Some NAGLU gene variants have been discovered to be associated with reduced N-acetyl-α-D-glucosaminidase (NAGLU) activity.

A Method For Measuring The Protease Activity Of C3 And C5 Convertase Of The Alternative Complement Pathway
view source
US Patent:

20180087087, Mar 29, 2018
Filed:

Mar 28, 2016
Appl. No.:

15/557929
Inventors:

- New Haven CT, US
Christen D. FORBES - North Haven CT, US
International Classification:

C12Q 1/37
Abstract:

A method for measuring the protease activity of a convertase of the alternative complement pathway is provided. The method typically comprises immobilizing a biotinylated C3b on a solid phase coated with a biotin binding protein. Substantially homogeneous components of the alternative complement pathway may be incubated with the immobilized C3b in a serum free and gelatin free buffer, to form a convertase. The activity of the convertase is generally measured with an immunoassay.

A Method For Measuring The Protease Activity Of Factor D Of The Alternative Complement Pathway
view source
US Patent:

20180074077, Mar 15, 2018
Filed:

Mar 29, 2016
Appl. No.:

15/557926
Inventors:

- New Haven CT, US
Christen D. FORBES - North Haven CT, US
International Classification:

G01N 33/86
C12N 9/50
Abstract:

A method for measuring the protease activity of Factor D for its natural substrate is provided. Factor D activity may be measured with an immunoassay or a biosensor. The method typically comprises immobilizing a biotinylated C3b on a solid phase coated with a biotin binding protein. Substantially homogeneous components of the alternative complement pathway may be incubated with the immobilized C3b to form a convertase. An immunoassay or a biosensor is generally used to measure the formation of Bb.